Related Experiment Video
Updated: Sep 20, 2025
10:44
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
10.4K
Thinking outside the box: non-canonical targets in multiple sclerosis.
Laura Bierhansl1, Hans-Peter Hartung2,3,4, Orhan Aktas2
1Department of Neurology, Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Nature Reviews. Drug Discovery
|June 6, 2022
Summary
Multiple sclerosis (MS) is a progressive neurological disease lacking a cure. This review explores novel, non-canonical therapeutic targets beyond current immunotherapies for MS treatment.
Area of Science:
- Neuroimmunology
- Neurology
Background:
- Multiple sclerosis (MS) is an immune-mediated central nervous system disease causing progressive neurological disability.
- Current immunotherapies have expanded but often fail to halt insidious MS progression, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review non-canonical therapeutic targets in preclinical multiple sclerosis (MS) research.
- To identify promising new avenues for MS treatment beyond established immunotherapies.
Main Methods:
- Literature review of preclinical research in multiple sclerosis.
- Focus on five emerging therapeutic target areas: oligodendrocytes, blood-brain barrier, metabolism, coagulation system, and tolerance induction.
Main Results:
- Identified five promising non-canonical target areas for MS therapy.
- Highlighted recent findings that may inform future therapeutic development.
Conclusions:
- Novel therapeutic targets in MS are emerging from preclinical research.
- Exploring non-canonical pathways offers potential for new and effective MS treatments.
